FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT:

(Use several sheets if necessary)

ATTY. DOCKET NO .:

065435-9014

Sheet 1 of 5

SERIAL NO.:

APPLICANT:

FILING DATE:

10/069,202

Thurston et al.

February 22, 2002

GROUP:

1624

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BIK.	1	3,523,941	11 Aug 1970	Leimgruber et al	260	239.3	,
ſ	2	3,524,849	18 Aug 1970	Batcho et al	260	739.3	
	3	4,239,683	16 Dec 1980	Takanabe et al	260	239.3	
	4	4,309,437	05 Jan 1982	Ueda et al	424	274	
7	5	5,143,854	01 Sep 1992	Pirrung et al	436	518	
V	6	5,545,568	13 Aug 1996	Ellman	436	518	

POREIGN	IAI.	DIAT 1	MINITAL	•
ĺ			 	
		l	- 1	

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
D.K.	7	1 299 198	06 Dec 1972	Great Britain	<u> </u>		
	8	2 586 683	06 Mar 1987	France			X
	9	WO 88/04659	30 June 1988	PCT/US			
	10	WO 91/16324	31 Oct 1991	PCT/US			
	11	WO 92/19620	12 Nov 1992	PCT/FR			X
	12	WO 96/23947	08 Aug 1996	PCT/US			
	13	WO 97/01560	16 Jan 1997	PCT/US			
	14	WO 97/07097	27 Feb 1997	PCT/NZ			
	15	WO 98/11101	19 Mar 1998	PCT/NZ			
	16	WO 99/29642	17 Jun 1999	PCT/US			
	17	WO 00/12506	09 Mar 2000	PCT/GB			
	18	57-131791	14 Aug 1982	Japan			X
V	19	58180487 A	21 Oct 1983	Japan			X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

N.V.	20	Althuis, T.H. et al., "Synthesis and identification of the major metabolites of Prazosin
$\mathcal{D} \vdash$		formed in dog and rat," 20:1, 146-149 (1977).
1	21	Aristoff, P.A. et al., "Synthesis of CBI-PDE-I-Dimer, the benzannelated analogue of CC-
	l	1065," J.Org.Chem.," 57, 6234-6239 (1992).
	22	Aristoff, P.A. et al., "Synthesis of biochemical evaluation of the CBI-PDE-I-dimer, a benzannelated
1		analog of (+)-CC-1065 that also produces delayed toxicity in mice," J.Med.Chem., 36, 1956-1963
		(1993).
	23	Baraldi, P.G. et al., "Design, synthesis and biological activity of a pyrrolo [2,I-c][1,4]
		benzodiazepine (PBD)-distamycin hybrid," Bioorg. Med. Chem. Ltrs., 8, 3019-3024 (1998).
	24	Bi, Y. et al, "Building blocks for peptide and carbamate libraries," Bioorg. Med. Chem.
1_		Ltrs, 6:19, 2299-2300 (1996).
\overline{V}	25	Bi, Y., et al, "Building blocks for peptide and carbamate libraries," Chemical Abstracts,
		300965y, 125:23, p.1013 (1996).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT:

(Use several sheets if necessary)

ATTY. DOCKET NO.:

065435-9014

Sheet 2 of 5

SERIAL NO.:

10/069,202

APPLICANT:

Thurston et al.

FILING DATE:

February 22, 2002

GROUP:

1624

B./C.	26	Boger, D.L., "Design, synthesis, and evaluation of DNA minor groove binding agents: the duocarmycins," <i>Pure & Appl. Chem.</i> , 66:4, 837-844 (1994).
	27	Boger, D.L. et al., "Total synthesis and evaluation of ±-N-(tert-butyloxycarbonyl)-CBI (±)-CBI-CDPI ₁ and (±)-CBI-CDPI ₂ CC-1065 functional agents incorporating the equivalent 1,2,9,9a-tetrahydrocycloprop[1,2-c]benz[1,2-e]indol-4-one(CBI) left-hand subunit," J. Am. Chem Soc., 111:16, 6461-6463 (1989).
	28	Boger, D.L. et al., "Synthesis of N-(tert-butyloxycarbonyl)-CBI,CBI,CBI-CDPI _I ,and CBI-CDPI ₂ : Enhanced functional analogues of CC-1065 incorporating the 1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI) left-hand subunit,". Org. Chem., 55:23, 5823-5832 (1990).
	29	Boger, D.L. et al., "An efficient synthesis of 1,2,9,9a-tetrahydrocyclopropa[c]benz[e] indol-4-one (CBI): An enhanced and simplified analog of the CC-1065 and duocarmycin alkylation subunits," J. Org. Chem., 60:5, 1271-1275 (1995).
	30	Boger, D.L. et al., "CBI-TMI: Synthesis and evaluation of a key analog of the duocarmycins. Validation of a direct relationship between chemical solvolytic stability and cytotoxic potency and confirmation of the structural features responsible for the distinguishing behavior of enantiomeric paris of agents," J. Am. Chem. Soc., 116:18, 7996-8006 (1994).
	31	Boger, D.L. et al., "CC-1065 and the duocarmycins: synthetic studies," Chem. Rev., 97:3, 787-828 (1997).
	32	Bose, D.S et al., "New approaches to pyrrolo[2,1-c][1,4]benzodiazepines: synthesis, DNA-binding and cytotoxicity of DC-81," <i>Tetrahedron</i> , 48:4, 751-758 (1992).
	33	Bose, D.S. et al., "Rational design of a highly efficient irreversible DNA interstrand cross-linking agent based on the pyrrolobenzodiazepine ring system," J. am. Chem. Soc., 114:12, 4939-4941 (1992).
	34	Brown, S.C. et al., "NMR solution structure of a peptide nucleic acid complexed with RNA," Science, 265, 777-780 (1994).
	35	Burgess, K. et al., "Solid phase syntheses of oligoureas," J. Am. Chem. Soc., 119:7, 1556-1564 (1997).
	36	Burgess, K. et al., "Solid-phase syntheses of unnatural biopolymers containing repeating urea units," Agnew. Chem. Int. Ed. Engl., 34:8, 907-909 (1995).
	37	Cava, M.P. & Drost, K.J., "A photochemically based synthesis of the benzannelated analogue of the CC-1065 A unit," <i>J. Org. Chem.</i> , 56:6, 2240-2244 (1991).
	38	Cho, C.Y. et al., "An unnatural biopolymer," Science, 261, 1303-1305 (1993).
	39	Courtney, S.M. et al., "A new convenient procedure for the synthesis of pyrrolo[2,1-c][1,4]benzodiazepines," <i>Tetrahedron Ltrs.</i> , 34:33, 5327-5328 (1993).
	40	Edman, P. et al., "A protein sequenator," European J. Biochem., 1:1, 80-91 (1967).
	41	Egholm, M. et al, "Peptide nucleic acids (PNA). Oligonucleotide analogues with an achiral peptide backbone," J. Am. Chem. Soc., 114, 1895-1897 (1992).
	42	Egholm, M. et al., "PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules," <i>Nature</i> , 365, 566-568 (1993).
1	43	Farmer, J.D., Jr. et al., "DNA binding properties of a new class of linked anthramycin analogs," <i>Chemical Abstract</i> , 239940r, 114:25, p.25 (1991).

EXAMINER

Bruch Zill

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

> INFORMATION DISCLOSURE STATEMENT BY APPLICANT:

(Use several sheets if necessary)

ATTY. DOCKET NO.:

065435-9014

Sheet 3 of 5

SERIAL NO.:

10/069,202

APPLICANT:

Thurston et al.

FILING DATE:

February 22, 2002

GROUP:

1624

	1 .	
B.K.	44	Figliozzi, G.M. et al., "Synthesis of N-substituted glycine peptoid libraries," Methods in Enzymology, 267:25 437-47 (1996).
1	45	Foloppe, M.P. et al., "DNA-binding properties of pyrrolo[2,1-c][1,4]-benzodiazepine
- 1	43	N10-C11 amidines," Eur. J. Med. Chem., 31, 407-410 (1996).
	46	Fujisawa Pharm., "Benzodiazepine derivatives," Chemical Abstracts, 139983k, 99:17
		603 (1983).
	47	Fujisawa Pharm., "Benzodiazepine derivatives," <i>Chemical Abstracts</i> , 72145x, 98:9, 638 (1983).
	48	Fukuyama, T. et al., "Total synthesis of (+)-porothramycin B," Tetrahedron Ltrs., 34:16, 2577-80 (1993).
	49	Furka, A. et al., "General method for rapid synthesis of multicomponent peptide
1		mixtures," In. J. Peptide Protein Res., 37 487-493 (1991).
	50	Gregson, S.J. et al., "Synthesis of a novel C2/C2'-exo unsaturated
		pyrrolobenzodiazepine cross-linking agent with remarkable DNA binding affinity and
	61	cytotoxicity," Chem. Commun., 797-798 (1999).
	51	Guiotto, A. et al., "Synthesis of novel C7-aryl substituted pyrrolo[2,1-
		c][1,4]benzodiazepines (PBDs) via pro-N10-troc protection and suzuki coupling,"
	-	Bioorg. Med. Chem. Ltrs., 8:21, 3017-3018 (1998).
	52	Hara, M. et al., "A new glycosidic pyrrolo[1,4]benzodiazepine antibiotic produced by
		streptomyces sp." J. Antibiotics, 41:5, 702-704 (1988).
ł	53	Hochlowski, J.E. et al., "Abbeymycin, a new anthramycin-type antibiotic produced by
		a streptomycete," J. of Antibiotics, 40:2, 145-148 (1987).
	54	Hurley, L.H. et al., "Covalent binding of antitumor antibiotics in the minor groove of DNA. Mechanism of action of CC-1065 and the pyrrolo[1,4]benzodiazepines," Acc. Chem. Res., 19, 230-237 (1986).
	55	Itoh, J. et al., "Sibanomicin, a new pyrrolo[1,4]benzodiazepine antitumor antibiotic
	33	produced by a micromonospora sp.," J. Antibiotics, 41:9,1280-1284 (1988).
1	56	Jenkins, T.C. et al., "Structure of a covalent DNA minor groove adduct with a
	30	pyrrolobenzodiazepine dimer: Evidence for sequence-specific interstrand cross-
1		linking," J. Med. Chem., 37:26, 4529-4537 (1994).
_	57	Kohn, K.W., "Anthramycin," Antibiotics, III, 3-11 (1975).
+	58	Konishi, M. et al., "Chicamycin, a new antitumor antibiotic II. Structure
	36	determination of chicamycins A and B," J. Antibiotics, 37:3, 200-206 (1984).
	59	Kunimoto, S. et al., "Mazethramycin, a new member of anthramycin group
		antibiotics," J. Antibiotics, 33:6, 665-667 (1980).
	60	Langley, D.R. et al., "A versatile and efficient synthesis of carbinolamine-containing
		pyrrolo[1,4]benzodiazepines via the cyclization of N-(2-aminobenzoyl)pyrrolidine-
1 1		2carboxaldehyde diethyl thioacetals: Total synthesis of prothracarcin," J. Organ. Chem.,
		52:1, 91-97 (1987).
1,	61	Leber, J.D. et al., "A revised structure for sibiromycin," J. Am. Chem. Soc., 110:9,

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 4 of 5

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-92) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT:

(Use several sheets if necessary)

ATTY. DOCKET NO .:

065435-9014

SERIAL NO.:

10/069,202

APPLICANT:

Thurston et al.

FILING DATE:

February 22, 2002

GROUP:

1624

Leimgruber, M. et al., "The structure of anthramycin," J. Am. Chem. Soc., 5793-5795 (1965). Leimbruger, M. et al., "Isolation and characterization of anthramycin, a ne antitumor antibiotic," J. Am. Chem. Soc., 87:24, 5791-5793 (1965). Lescrinier, T. et al., "DNA-binding ligands from peptide libraries containing unnatural amino acids," Chem. Eur. J., 4:3, 425-433 (1998). Lown, J.W. et al., "Antitumor antibiotics," Biochem. Pharmacol., 28:13, 2	ew ing 2017-2026
antitumor antibiotic," J. Am. Chem. Soc., 87:24, 5791-5793 (1965). 64 Lescrinier, T. et al., "DNA-binding ligands from peptide libraries containing unnatural amino acids," Chem. Eur. J., 4:3, 425-433 (1998). 65 Lown, J.W. et al., "Antitumor antibiotics," Biochem. Pharmacol., 28:13, 2	ing 2017-2026
unnatural amino acids," Chem. Eur. J., 4:3, 425-433 (1998). 65 Lown, J.W. et al., "Antitumor antibiotics," Biochem. Pharmacol., 28:13, 2	2017-2026
65 Lown, J.W. et al., "Antitumor antibiotics," Biochem. Pharmacol., 28:13, 2	
(1979).	
Monks, A. et al., "Feasibility of a high-flux anticancer drug screen using a panel of cultured human tumor cell lines," J. of Nat'l Cancer Inst., 83:11, (1991).	
67 Moran, E.J. et al., "Novel biopolymers for drug discovery," Peptide Science 219 (1995).	ce, 37, 213-
Nagasaka, T. et al., "Stereoselective synthesis of tilivalline," Tetrahedron 30:14, 1871-1872 (1989).	Letters,
69 Nagasaka, T. et al., "Stereoselective synthesis of tilivalline," J. Org. Chem 6797-6801 (1998).	n., 63:20,
Nielsen, P.E. et al., "Sequence-selective recognition of DNA by strand diswith a thymine-substituted polyamide," Science, 254, 1497-1500 (1991).	placement
71 O'Neil, Ian et al., "The synthesis of functionalized pyrrolo[2,1-e][1,4]-benzodiazepines," Chemical Abstracts, 126:13, 618 (1997) and entire artic	cle.
72 O'Neil, Ian A. et al., "DPPE: A convenient replacement for triphenylphos Staudinger and Mitsunobu reactions," Tetrahedron Letters, 39:42, 7787-77	sphine in the 790 (1998).
Paikoff, S.J. et al., "The solid phase synthesis of N-alkylcarbamate oligom Tetrahedron Letters, 37:32, 5653-5656 (1996).	iers,"
Rawal, V.H. <i>et al.</i> , "Photocyclization strategy for the synthesis of antitumod CC-1065: Synthesis of dideoxy PDE-I and PDE-II. Synthesis of Thiophene analogues of dideoxy PDE-I and PDE-II, <i>J. Org. Chem.</i> , 52:1, 19-28 (1987)	e and Furan
75 Reynolds, V.L. et al., "The chemistry, mechanism of action and biological of CC-1065, a potent antitumor antibiotic," J. Antibiotics, 39:3, 319-334 (1)	l properties
76 Saha, A.K. <i>et al.</i> , "Diisopropylsilyl-linked oligonucleotide analogs: Solid-p synthesis and physicochemical properties," <i>J. Org. Chem.</i> , 58:27, 7827-78.	phase
77 Schreiber, S.L., Kapoor, T.M. et al., "Exploring the specificity pockets of the homologous SH3 domains using structure-based, split-pool synthesis and a based selection," J. Am. Chem. Soc., 120:1, 23-29 (1998).	
78 Shimizu, K. et al., "Prothracarcin, a novel antitumor antibiotic," J. Antibiol. 972-978 (1982).	tics, 35:8,
79 Simon, R.J. et al., "Peptoids: A modular approach to drug discovery," Pro Acad. Sci. USA, 89, 9367-9371 (1992).	oc. Natl.
Soth, M.J. et al., "Unnatural oligomers and unnatural oligomer libraries," (Chem. Biol., 1:1, 120-129 (1997).	Curr. Opin.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

> INFORMATION DISCLOSURE STATEMENT BY APPLICANT:

(Use several sheets if necessary)

ATTY. DOCKET NO .:

065435-9014

Sheet 5 of 5

10/069,202

Thurston et al.

February 22, 2002

FILING DATE: GROUP:

SERIAL NO.:

APPLICANT:

1624

1.K.	81	Takeuchi, T. et al., "Neothramycins A and B, new antitumor antibiotics," J.
<u> </u>		Antibiotics, 29:1, 93-96 (1976).
i	82	Thurston, D.E. et al., "Synthesis of DNA-interactive pyrrolo[2,1-
		c][1,4]benzodiazepines," Chem. Rev. 94:2, 433-465 (1994).
	83	Thurston, D.E. et al., "The molecular recognition of DNA," Chem. Britain, 26, 767-
- 1		772 (1990).
	84	Thurston, D.E. et al., "Synthesis of a novel GC-specific covalent-binding DNA
Ī	i	affinity-cleavage agent based on pyrrolobenzodiazepines (PBDs)," Chem. Commun.,
ı		563-565 (1996).
	85	Thurston, D.E., "Advances in the study of pyrrolo[2,1-c][1,4]benzodiazepine (PBD)
1	"	antitumour antibiotics," Molecular Aspects of Anticancer Drug-DNA Interaction,
- 1		Neidle, S., Waring, M.J., Eds.; Macmillan Press Ltd., v.1, 54-88 (1993).
-	86	Thurston, D.E. et al., "Effect of A-ring modifications on the DNA-binding behavior
1	00	
		and cytotoxicity of pyrrolo[2,1-c],[1,4]benzodiazepines," J. Med. Chem. 42:11, 1951-
	-	1964 (1999).
l l	87	Tsunakawa, M. et al., "Porothramycin, a new antibiotic of the anthramycin group:
1		production, isolation, structure and biological activity," J. Antibiotics, 41:10, 1366-
		1373 (1988).
	88	Umezawa, H. et al., "Mazethramycins," Chemical Abstracts, 90:1, 428 (1979).
1	89	Wilson, S.C. et al., "Design and Synthesis of a novel epoxide-containing pyrrolo[2,1-
)		c][1,4]benzodiazepine (PBD) via a new cyclization procedure," Tetrahedron Ltrs.,
1		36:35, 6333-6336 (1995).
	90	Zuckermann, R.N. et al., "Discovery of nanomolar ligands for 7-transmembrane G-
1,		protein-coupled receptors from a diverse N-(substituted)blycine peptoid library," J.
V		Med. Chem., 37:17, 2678-2685 (1994).
		111cu. Chem., 37.11, 2010-2003 (1777).

Q:\CLIENT\065435\9014\B0135416.1

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.